Table 1.
Participant Information.
| Participant | Age | Gender | Intelligibility | Time since diagnosis (years) | Medication |
|---|---|---|---|---|---|
| PD1 | 66 | M | 668 | 4 | Sinemet, Sinemet CR, Entacapone |
| PD2 | 71 | M | 748 | 3 | Madopar |
| PD3 | 75 | M | 486 | 6 | Madopar |
| PD4 | 62 | M | 675 | 6 | Bezhexol, Co-Codamol, Amlodipine, Bendropfluazide, Sinemet Plus, Ropinirole |
| PD5 | 67 | M | 533 | 11 | Sinemet, Selegiline, Pergolide, Entacapone |
| PD6 | 62 | M | 438 | 10 | Amantadine, Sinemet, Ropinirole |
| PD7 | 71 | M | 464 | 10 | Sinemet, Domperidone |
| PD8 | 71 | M | 581 | 11 | Selegiline, Sinemet CR, Madopar, Entacapone |
| PD9 | 60 | M | 725 | 5 | Pramipexole, Finasteride, Co-Codamol, Quinine bisulphate |
| PD10 | 77 | M | 568 | 6 | Madopar |
| CON1 | 64 | M | 701 | ||
| CON2 | 70 | M | 850 | ||
| CON3 | 74 | M | 592 | ||
| CON4 | 62 | M | 538 | ||
| CON5 | 66 | M | 766 | ||
| CON6 | 77 | M | 777 | ||
| CON7 | 69 | M | 583 | ||
| CON8 | 59 | M | 752 | ||
| CON9 | 67 | M | 719 | ||
| CON10 | 73 | M | 753 |
PD = speaker with Parkinson’s Disease; CON = Control speaker. Intelligibility values reflect the Direct Magnitude Estimation (DME) score, where 100 represents a PD speaker with moderate dysarthria. Increasing scores correspond to higher levels of intelligibility.